

Hong Kong Exchange, and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the content, for any inaccuracies, or for any omissions, and expressly disclaim any liability whatsoever for any loss or damage, in whole or in part, arising from the use of the content, for any inaccuracies, or for any omissions.



JOINN LABORATORIES (CHINA) CO., LTD.

北京昭衍新藥研究中心股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6127)

ESTIMATED RESULTS FOR THE HALF YEAR OF 2023

JOINN LABORATORIES (CHINA) CO., LTD. (the "Company") is listed on the Main Board of the Hong Kong Stock Exchange (the "Hong Kong Listing Rules") under the listing number 6127. The Company's share code is 0571.

I. ESTIMATED RESULTS FOR THE HALF YEAR OF 2023

(I) Estimated Results for the Half Year of 2023

From 1 June 2023 to 30 June 2023.

(II) Estimated Results for the First Half of 2023

The Board of Directors (the "Board") of the Company has estimated the results for the first half of 2023 (the "First Half of 2023") for the period from 1 January 2023 to 30 June 2023.

1. Income		First Half 2023	
Revenue	RMB973.2332 million	RMB1,050.9213 million	25.3%
Profit	RMB196.3521 million	RMB274.0402 million	35.3%

III. MAIN REASONS FOR THE CHANGE IN RESULTS DURING THE PERIOD

- (I) 2023年, 公司营业收入较上年同期增加, 主要系公司加大市场开拓力度, 营业收入增加所致。
- (II) 2023年, 公司营业成本较上年同期增加, 主要系公司加大市场开拓力度, 营业成本增加所致。
- (III) 2023年, 公司期间费用较上年同期增加, 主要系公司加大市场开拓力度, 期间费用增加所致。

IV. RISK WARNING

V. OTHER EXPLANATION

A. 2023年, 公司营业收入较上年同期增加, 主要系公司加大市场开拓力度, 营业收入增加所致。

B. 2023年, 公司营业成本较上年同期增加, 主要系公司加大市场开拓力度, 营业成本增加所致。

C. 2023年, 公司期间费用较上年同期增加, 主要系公司加大市场开拓力度, 期间费用增加所致。

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

B
JOINN Laboratories (China) Co., Ltd.
Feng Yuxia
Chairman

2023年11月14日

At the date of this announcement, the Board comprises Mr. Feng Yuxia, the Chairman and executive Director, Mr. Zhang Conglin, Mr. Gao Daeng, Mr. Shen Yanyan and Dr. Yadalin, the executive Director, and Mr. Song Mingcheng, Dr. Zhai Yingng, Mr. O. Xiajie and Mr. Zhang Fan, independent non-executive Directors.